WO2002062386A2 - Photodynamic therapy of occult choroidal neovascularization linked to age-related macular degeneration - Google Patents
Photodynamic therapy of occult choroidal neovascularization linked to age-related macular degeneration Download PDFInfo
- Publication number
- WO2002062386A2 WO2002062386A2 PCT/US2002/003758 US0203758W WO02062386A2 WO 2002062386 A2 WO2002062386 A2 WO 2002062386A2 US 0203758 W US0203758 W US 0203758W WO 02062386 A2 WO02062386 A2 WO 02062386A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lesion
- phthalocyanine
- subject
- zinc
- visual acuity
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Definitions
- the invention relates to a method to treat occult age-related macular degeneration by administering photodynamic therapy (PDT) to the eye.
- PDT photodynamic therapy
- Age-related macular degeneration causes severe, irreversible vision loss and is the leading cause of blindness in individuals older than 50 years in the Western World.
- the Framingham study reported the prevalence of AMD in the United States as 1.2% of the population between 52 and 64 years of age, with an increase to 20% in patients over the age of 75.
- the Beaver Dam Eye Study reported an incidence of 37% in patients 75 years and older.
- Most patients have the non-neovascular (“dry") form, characterized by drusen and atrophic changes in the retinal pigment epithelium (RPE). Eighty to ninety percent of the severe vision loss due to AMD, however, is attributable to the form characterized by choroidal neovascularization (CNN), also called "wet" AMD.
- CNN choroidal neovascularization
- C ⁇ V is an ingrowth of choroidal capillaries through a break in the outer aspects of Bruch's membrane.
- choroidal capillaries In the United States, between 70,000-200,000 individuals over the age of 65 develop the wet form of AMD every year. Slightly lower estimates of prevalence and incidence of C ⁇ V secondary to AMD have been reported in the Netherlands but higher estimates have been found in England. The great majority of wet AMD occurs subfoveally.
- CNV in wet AMD can be generally divided into two classes, "classic” CNN” and “occult” C ⁇ N. The two forms are distinguishable by angiography conducted with fluorescein dye.
- Classic C ⁇ V is generally defined by a well-demarcated area of bright hyperfluorescence throughout the transit phase of the angiogram with leakage in the mid and late phase frames. Vessels of the neovascular lesion often will be visualized in the early phase of the angiogram, but are not required to be identified..
- Occult C ⁇ V includes fibrovascular pigment epithelial detachment (a type of occult choroidal neovascularization in which areas of irregular elevation of the retinal pigment epithelium are detectable on stereoscopic angiography and consists of an area of stippled hyperfluorescence noted within 1 to 2 minutes after fluorescein injection). Persistence of fluorescein staining or leakage within this area occurs within 10 minutes after fluorescein injection. These areas are not as discrete or bright as areas of classic choroidal neovascularization or serious detachment of the retinal pigment epithelium in the early phase of the angiogram.
- occult CNN may show late leakage ofan undetermined source (a type of occult choroidal neovascularization in which areas of leakage at the level of the retinal pigment epitherim in the late phase of the angiogram are without well-demarcated areas of hyperfluorescence from classic C ⁇ V or a fibrovascular pigment epithelial detachment discernible in the early phase of the angiogram that account for the leakage.)
- an undetermined source a type of occult choroidal neovascularization in which areas of leakage at the level of the retinal pigment epitherim in the late phase of the angiogram are without well-demarcated areas of hyperfluorescence from classic C ⁇ V or a fibrovascular pigment epithelial detachment discernible in the early phase of the angiogram that account for the leakage.
- a C ⁇ V lesion can be comprised only of occult C ⁇ V, which is termed occult C ⁇ V with no classic C ⁇ V. Some lesions comprise both classic and occult C ⁇ V.
- a lesion in which the area of classic C ⁇ V occupies more than 0%, but less than 50% is termed "minimally classic”.
- a lesion in which the area of classic C ⁇ V occupies at least 50% of the area of the entire lesion is termed "predominantly classic.”
- C ⁇ V the newly formed vessels have a tendency to leak blood and fluid, causing symptoms of scotoma and metamorphopsia.
- the new vessels are accompanied by proliferation of fibrous tissue.
- This complex of new vessels and fibrous tissue can destroy photoreceptors within 3 to 24 months.
- C ⁇ V is destroying retinal tissue where it has formed, the lesion can continue to grow throughout the macula, resulting in progressive, severe and irreversible vision loss. Without treatment, most affected eyes will have poor central vision ( ⁇ 20/200) within 2 years.
- the fellow eye has about a 50% chance of developing a similar C ⁇ V lesion within 5 years.
- Photodynamic therapy with verteporfin (VISUDYNETM , Novartis Ophthalmics) offers an approach to selectively destroy CNV without significant destruction of overlying retina tissue, possibly by occluding the new vessels within the CNN lesion.
- Photodynamic therapy is a two-step process consisting of an intravenous injection of a photosensitizer (light-activated drug) followed by light application.
- the light sources most commonly used are non-thermal lasers or light emitting diodes (LEDs).
- Verteporfin preferentially accumulates in neovascular tissues, including the endothelial cells of choroidal neovascularization. In combination with localized light administration, this allows for selective treatment of the pathologic tissue. After exposure to light at a wavelength of 689nm, an energy transfer cascade is initiated, culminating in the formation of singlet oxygen which generates intracellular free radicals. These free radicals can disrupt cellular structures such as the cell membrane, mitochondria, and lysosomal membranes.
- Occlusion of the neovasculature is presumed to be the major mechanism of PDT with verteporfin. Occlusion can occur through free radical damage to the endothelial cells, causing subsequent platelet adhesion and degranulation, and thrombus formation. A reduction in blood flow from the new vessels may lead to a confinement in the growth of the fibrovascular C ⁇ V lesion with subsequent reduced risk of further vision loss compared with no treatment. Thus, verteporfin PDT reduces the area of the macula affected by C ⁇ V and spares viable photoreceptors from destruction caused by fibrovascular disorganization of the outer retina.
- Photodynamic therapy of neovascular conditions in the eye has been attempted over the past several years using a variety of photosensitive compounds, e.g. porphyrin derivatives, such as hematoporphyrin derivative and porfimer sodium (PHOTOFRI ⁇ ® Axcan Pharmaceuticals), phthalocyanines , green porphyrins (such as verteporfin, also known as BPD-MA), purpurins, such as tin ethyl etiopurpurin and texaphyrins, such as motexafin lutetium.
- the photosensitive compound verteporfin (VisudyneTM, Novartis Ophthalmics) is the only photosensitive compound to have received regulatory approval (from the U.S.
- the invention is directed to a method to treat occult CNV lesions using photodynamic therapy.
- "Occult lesions” as used herein refer to CNN lesions which have an occult C ⁇ V component, preferably comprising 50% to 100% of the lesion, and lesions that are defined as minimally classic that have an occult component.
- C ⁇ V characterized by lesions having an occult component comprising at least about (and including) 50% to about (and including) 100% of the lesion may be herein referred to as "occult C ⁇ V.”
- Results of a study outlined in Example 3 below show that subjects having occult lesions respond to PDT carried out using the photoactive compound verteporfin. This was surprising, in view of a study (Arch Ophthalmol.
- Subjects can be divided on the basis of best corrected visual acuity prior to treatment (baseline visual acuity) into those having poor visual acuity prior to treatment and those having relatively good visual acuity.
- Poor visual acuity means generally a best corrected vision of less than 65 letters on an ETDRS chart (see Example 1 below), corresponding to a visual acuity of less than about 20/50 or worse.
- Good visual acuity generally means a best corrected vision of at least 65 letters, corresponding to a visual acuity of about 20/50 or better. All subjects having poor visual acuity at baseline had a great benefit from PDT treatment of their C ⁇ V lesion.
- subjects having good visual acuity prior to treatment benefit from PDT treatment if the size of their lesion is small, generally less than about 4-5 Disc Areas (see Example 2 below), which corresponds to a lesion size of less than about 10 to 13 mm .
- Subjects having good visual acuity and large lesion size larger lesion size do not appear to benefit from treatment with PDT compared to placebo controls. All subjects having a small lesion size benefited from treatment. This was a very surprising result, because there was no reason to anticipate this differential pattern of response to PDT. Without being bound by theory, the expectation might have been that subjects having larger lesions generally would experience a greater benefit of PDT than those having smaller lesions. Having discovered the sub-populations of occult subjects that benefit from PDT, it has been possible to design a method to treat occult CNV so that the chances of preserving visual acuity in treated subjects is substantial.
- the invention is directed to a method of treating a subject having an occult choroidal neovascular lesion, comprising the steps of:
- PDT photodynamic therapy
- the invention provides methods for treating an occult choroidal neovascular lesion in a subject comprising providing photodynamic therapy to a subject assessed as having either or both of (a) a small lesion or (b) poor visual acuity.
- the assessment of the subject may be by determining the size of said lesion and/or determining the best corrected visual acuity of the subject.
- PDT comprises the steps of
- the subject is evaluated angiographically for evidence of new neovascular leakage at least every three months, and if new leakage has occurred, the PDT treatment is repeated.
- the visual acuity of the subject at baseline is less than about (and including) 65 letters in the practice of the invention.
- the small lesion size is less than about 4-5 disc areas, most preferably less than about 4 Disc Areas.
- a particular embodiment useful for PDT treatment of predominantly classic CNV with verteporfin includes the administration by infusion of verteporfin in a liposomal formulation know as Verteporfin for Injection (VFI) over a period of 10 minutes, and subsequent irradiation with light at a wavelength of (689+ /-3nm) that activates the verteporfin at approximately 15 minutes after the start of the infusion.
- VFI Verteporfin for Injection
- Animal studies have demonstrated that the elapsed time between drug administration and light is a very important variable in the treatment of neovascular conditions with PDT (see U.S. Patent No. 5,770,619).
- Pharmacokinetic studies have shown that photosensitive compound accumulates preferentially in neovasculature, but eventually permeates other tissue as well.
- the present invention is based in part upon the recognition that with occult lesions, which are more fibrous, delaying light application slightly improves the outcome of treatment.
- the invention is directed to the above method wherein the administration of light is delayed until about 30 minutes after the start of administration of the photoactive compound.
- the invention is directed to a method of selecting subjects having an occult choroidal neovascular lesion who will benefit from photodynamic therapy, comprising:
- FIG. 1 is a drawing of preferred forms of the green porphyrins useful in the methods of the invention.
- Figure 2 is a drawing of the chemical structure of verteporfin, which has two regioisomers.
- the present invention is generally directed to treating occult choroidal neovascularization (CNN) lesions with photodynamic therapy (PDT).
- CNN occult choroidal neovascularization
- PDT photodynamic therapy
- a human patient who has been diagnosed with occult C ⁇ V, is suspected of having, or is otherwise afflicted with occult C ⁇ V is assessed angiographically to determine the size of the C ⁇ V lesion.
- the patient is also assessed for best corrected visual acuity. If the subject has either or both of (a) a lesion size of less than about 4-5 Disc Areas, or (b) a best corrected visual acuity of less than about 65 letters, then the subject is identified as being a candidate for treatment with photodynamic therapy.
- the patient is then administered a suitable photoactive compound in amount sufficient to provide an effective concentration of the photoactive compound to localize in the target neovasculature.
- a suitable time period to permit an effective concentration of the compound to accumulate in the ocular neovasculature
- this region is irradiated with light absorbed by the photoactive compound.
- the irradiation results in excitation of the compound which, in turn, causes damage to the immediately surrounding tissue, which results in closure of neovasculature, and cessation of leakage. This procedure is repeated as required based upon periodic angiographic evaluations.
- the invention utilizes PDT methods which generally include the administration of a photosensitizer (PS) and irradiation with a wavelength of electromagnetic radiation capable of activating the PS.
- PS photosensitizer
- the invention also includes use of a PS in the preparation of a medicament for use in any of the methods described herein.
- Visual acuity means best corrected visual acuity.
- visual acuity is assessed.
- the assessment is done using a retroilluminated Lighthouse for the Blind (New York, N.Y.) distance visual acuity test chart, using modified Early Treatment Diabetic Retinopathy Study (ETDRS) charts 1 , 2, and R), the methodology for which is outlined in detail in Example 1 below.
- EDRS Early Treatment Diabetic Retinopathy Study
- Another chart such as a typical Snellen eye chart can also be used if an ETDRS chart is not available.
- an ETDRS chart is preferred, as it gives a more precise measurement of visual acuity.
- ETDRS eye charts in determining visual acuity is explained in Arch. Ophthalmol. 1991 109: 1242-1257, which is incorporated herein in its entirety.
- the ETDRS charts have 5 letters per line and a doubling of the minimum angle of resolution every 3 lines. Best corrected visual acuity is scored based on the total number of correct letters identified at a distance of 2 meters, plus 15. If a subject reads fewer than 20 letters at 2 meters, the subject is tested on the top 3 lines at 1 meter, and the score is the total number of letters read at 2 meters plus the total number of letters read a 1 meter.
- a visual acuity score of 65 and 73 letters corresponds to about 20/50 and 20/40, respectively, on a Snellen eye chart.
- a visual acuity of 34 letters corresponds to 20/200.
- Potential candidates for photodynamic therapy may have a best corrected visual acuity score of about 65 letters or less (unless the size of their lesion is small, as described below).
- determining the visual acuity of a subject is not a precise measurement, and can vary from day to day for reasons having to do with the subject's general health or mood. Therefore, it is likely that such measurements will vary by approximately + or - 10% or so, and the figure of 65 letters or less is meant to encompass such deviations.
- Lesion size may be determined by reference to angiographic photographs taken in rapid succession after the injection of fluorescein dye, as is commonly known in the art.
- a drawing of the lesion, including all of its components can be made by projecting the film on a microfilm reader using techniques described in Arch. Ophthalmol. 1991 109: 1242-1257. Such a drawing can be used for estimating the size of a lesion.
- lesion size is calculated in terms of "Disc Areas" (DA) which is a number corresponding to the entire area of a lesion, rather than to the diameter of the lesion, because a lesion is usually not perfectly round.
- DA Disc Areas
- the size of a lesion for the purposes of this invention refers to the entire neovascular lesion, which may be considered to be constituted by the entire complex of lesion components, including a choroidal neovascularization (classic or occult), thick blood, elevated blocked fluorescence (due to a pigment or scar that obscures the neovascular borders), and serous detachments of the retinal pigment epithelium.
- the number of disc areas covered by a lesion can be determined by reference to a graded series of "circles" of a defined diameter provided on a transparent overlay, which can be superimposed on the angiograph, as described in. in Arch. Ophthalmol. 1991 109: 1242-1257.
- a lesion size of 1 DA corresponds to an area of 2.5 square millimeters, assuming a disc diameter of 1.6 millimeters.
- a lesion size of 9 DA corresponds to an area of 5.4 square millimeters.
- Other methods of comparatively grading lesion sizes can be devised by those skilled in the art. A detail example of how to assess lesion size appears in Example 2 below.
- a small lesion is generally smaller than about 5 Disc areas (corresponding to an lesion having an area in the eye of about 13 mm 2 ), and preferably no larger than about 4 DA areas (corresponding to an lesion having an area in the eye of about 10 mm 2 ).
- determining the lesion size is not a precise art, especially when the lesion has an irregular shape, and that for example, a lesion measured as 5.5 DA might be considered a small lesion under some circumstances.
- a table showing the conversion of DA to area of lesion is found in Table 1 below.
- the photodynamic therapy according to the invention can be performed using any of a number of photoactive compounds.
- various derivatives of hematoporphyrin have been described, including improvements on hematoporphyrin derivative per se such as those described in U.S. Patent Nos. 5,028,621; 4,866,168; 4,649,151; and 5,438,071, the entire contents of which are incorporated herein by reference.
- pheophorbides are described in U.S. Patent Nos. 5,198,460; 5,002,962; and 5,093,349; bacteriochlorins in U.S. Patent Nos. 5,171,741 and 5,173,504. The contents of these patents are also incorporated herein by reference.
- Patent No. 5,079,262 describes the use of a precursor to hematoporphyrin, aminolevulinic acid (ALA), as the source of a photoactive compound.
- ALA aminolevulinic acid
- phthalocyanine photosensitive compounds in photodynamic therapy is described in U.S. Patent No. 5,166,197.
- Other possible photoactive compounds include purpurins (such as tin-ethyl etiopurpurin), merocyanines, iminochlorinaspartic acid derivative (U.S. Patent No. 6,063,777), texaphyrins (such as motexafin lutetium) and porphycenes.
- Particular preferred photoactive compounds for use in the invention method are the green porphyrins. These porphyrins are described in U.S. Patent Nos. 4,883,790; 4,920, 143; 5,095,030; and 5,171,749, the entire contents of which are incorporated herein by reference. As these photoactive agents represent a particularly preferred embodiment, typical formulas for these compounds are represented herein in Figure 1.
- Particularly prefe ⁇ ed green porphyrins for the practice of the invention are compounds such as BPD-DA, -DB, -MA, and -MB, and in particular BPD-MA, EA6, and B3.
- These compounds are porphyrin derivatives obtained by reacting a porphyrin nucleus with an alkyne in a Diels-Alder type reaction to obtain a monohydrobenzoporphyrin as described in U.S. Pat. No. 5,171,749, which is hereby incorporated in its entirety by reference.
- Other photosensitizers that may be used in the present invention include those described in U.S.
- Patents 5,308,608, 6,093,739, 5,703,230, 5,831,088, 5,726,304, and 5,405,957 It is prefe ⁇ ed that the absorption spectrum of the photoactive compound be in the visible range, typically between 350 nm and 1200 nm, more preferably between 400-900 nm, and even more preferably between 600-900 nm. Generally, any polypy ⁇ olic macrocyclic photoactive compound may be used in the practice of the invention.
- photosensitizer As used herein, the terms "photosensitizer,” “photosensitive compound,” “PS,” and “photoactive compound(s)” are used interchangeably. Any variation in meaning between these terms is not meant to depart form the gist and scope of the claimed invention.
- Particularly prefe ⁇ ed PSs are the green porphyrins, such as BPD-DA, -DB, -MA, and -MB, and in particular BPD-MA, EA6, and B3.
- BPD-DA porphyrin-DA
- -DB porphyrin-DB
- -MA -MA
- -MB -MB
- BPD-MA porphyrin derivatives obtained by reacting a porphyrin nucleus with an alkyne in a Diels-Alder type reaction to obtain a monohydrobenzoporphyrin, and they are described in detail in the issued U.S. Pat. No. 5,171,749, which is hereby incorporated in its entirety by reference.
- combinations of photosensitizers may also be used.
- Verteporfin as well as illustrations of A and B ring forms of EA6 and B3, are as follows:
- Exemplary angelicins include 3-aceto-angelicin; angelicin; 3,4'-dimethyl angelicin; 4,4'-dimethyl angelicin; 4,5'-dimethyl angelicin; 6,4'-dimethyl angelicin; 6,4-dimethyl angelicin; 4,4',5'-trimethyl angelicin; 4,4',5'-trimethyl- -thioangelicin; 4,6,4'-trimethyl-l'-thioangelicin; 4,6,4'-trimethyl angelicin; 4,6,5'-trimethyl-l'-thioangelicin; 6,4,4'-trimethyl angelicin; 6,4',5'-trimethyl angelicin; 4,6,4', 5'-tetramethyl-l'-thioangelicin; and 4,6,4', 5'-tetramethyl angelicin.
- Exemplary chalcogenapyrillium dyes include pyrilium perchlorate, 4,4'-(l,3-propenyl)-bt_»[2,6-di(l,l-dimethylethyl)]-; pyrilium perchlorate, 2,6-6 ⁇ (1,1- dimethyl-ethyl)-4-[l-[2,6-bt5(l,l-dimethyl-ethyl)selenopyran-4-ylidene]-3-propenyl-; pyrilium hexofluoro phosphate, 2,6-t ts-(l,l-dimethyl-ethyl)-selenopyran-4-ylidene]-3- propenyl-; pyrilium hexofluoro phosphate, 2,6-bts(l,l-dimethyl-ethyl)-selenopyran-4- ylidene]-3-propenyl-; pyr
- chlorins dyes include 5-azachlorin dimethyl ester derivative; 5,10,15,20-tetrakis-(m-hydroxyphenyl) bacteriochlorin; benzoporphyrin derivative monoacid ring A; benzoporphyrin derivative monoacid ring-A; porphine-2,18- dipropanoic acid, 7-[2-dimethyl-amino)-2-oxoethyl]-8-ethylidene-7,8-dihydro-3,7,12,17- tetramethyl, dimethylester; porphine-2,18-dipropanoic acid, 7-[2-dimethyl-amino)-2- oxoethyl]-8-ethylidene-8-ethyl-7,8-dihydro-3,7,12,17-tetramethyl, dimethylester Z; porphine-2,18-dipropanoic acid, 7-[2-dimethyl-amino)
- chlorophylls dyes include chlorophyll a; chlorophyll b; oil soluble chlorophyll; bacteriochlorophyll a; bacteriochlorophyll b; bacteriochlorophyll c; bacteriochlorophyll d; protochlorophyll; protochlorophyll a; amphiphilic chlorophyll derivative 1; and amphiphilic chlorophyll derivative 2.
- Exemplary coumarins include 3-benzoyl-7-methoxycoumarin; 7-diethylamino-3- thenoylcoumarin; 5,7-dimethoxy-3-(l-naphthoyl) coumarin; 6-methylcoumarin; 2H- selenolo[3,2-g] [1] benzopyran-2-one; 2H-selenolo[3,2-g] [1] benzothiopyran-2-one; 7H- selenolo[3,2-g] [1] benzoseleno-pyran-7-one; 7H-selenopyrano[3,2-fJ [1] benzofuran-7- one; 7H-selenopyrano[3,2-f] [1] benzo-thiophene-7-one; 2H-thienol[3,2-g] [1] benzopyran-2-one; 7H-thienol[3,2-g] [1] benzothiopyran-7-one; 7H
- Exemplary fullerenes include C 60 ; C 70 ; C 6 ; dihydro-fullerene; 1 ,9-(4-hydroxy- cyclohexano)-buckminster-fullerene; [ 1 -methyl-succinate-4-methyl-cyclohexadiene-2,3]- buckminster-fullerene; and tetrahydro fullerene.
- Exemplary metallopo ⁇ hyrins include cadmium (II) chlorotexaphyrin nitrate; cadmium (II) me5o-diphenyl tetrabenzopo ⁇ hyrin; cadmium /Me5 ⁇ -tetra-(4-N- methylpyridyl)-po ⁇ hine; cadmium (II) texaphyrin; cadmium (II) texaphyrin nitrate; cobalt ⁇ we5 ⁇ -tetra-(4-N-methylpyridyl)-po ⁇ hine; cobalt (II) ⁇ ne5 ⁇ (4-sulfonatophenyl)- po ⁇ hine; copper hematopo ⁇ hyrin; copper me5 ⁇ -tetra-(4-N-methylpyridyl)-po ⁇ hine; copper (II) we5 ⁇ (4-sulfonatopheny
- Exemplary metallophthalocyanines include aluminum mono-(6-carboxy-pentyl- amino-sulfonyl)-trisulfo-phthalocyanine; aluminum di-(6-carboxy-pentyl-amino- sulfonyl)-trisulfophthalocyanine; aluminum (III) octa-n-butoxy phthalocyanine; aluminum phthalocyanine; aluminum (III) phthalocyanine disulfonate; aluminum phthalocyanine disulfonate; aluminum phthalocyanine disulfonate (cis isomer); aluminum phthalocyanine disulfonate (clinical prep.); aluminum phthalocyanine phthalimido-methyl sulfonate; aluminum phthalocyanine sulfonate; aluminum phthalocyanine trisulfonate; aluminum (III) phthalocyanine trisulfonate; aluminum (III) phthalocyanine tetrasulfonate;
- Exemplary methylene blue derivatives include 1 -methyl methyl ene blue; 1,9- dimethyl methylene blue; methylene blue; methylene blue (16 ⁇ M); methylene blue (14 ⁇ M); methylene violet; bromomethylene violet; 4-iodomethylene violet; 1,9- dimethyl-3-dimethyl-amino-7-diethyl-amino-phenothiazine; and 1 ,9-dimethyl-3- diethylamino-7-dibutyl-amino-phenothiazine.
- Exemplary naphthalimides blue derivatives include N,N-bis-(hydroperoxy-2- methoxyethyl)-l,4,5,8-naphthaldiimide; N-(hydroperoxy-2-methoxyethyl)-l,8- naphthalimide; l,8-naphthalimide; N,N-bis(2,2-dimethoxyethyl)-l,4,5,8- naphthaldiimide; and N,N-bis(2,2-dimethylpropyl)-l ,4,5,8-naphthaldiimide.
- Exemplary naphthalocyanines include aluminum t-butyl-chloronaphthalocyanine; silicon 6/5(dimethyloctadecylsiloxy) 2,3 -naphthalocyanine; silicon 6/5(dimethyloctadecylsiloxy) naphthalocyanine; silicon 6/5(dimethylthexylsiloxy) 2,3- naphthalocyanine; silicon 6/5(dimethylthexylsiloxy) naphthalocyanine; silicon bis(t- butyldimethylsiloxy) 2,3 -naphthalocyanine; silicon 6/5(tert-butyldimethylsiloxy) naphthalocyanine; silicon 6/5(tri-n-hexylsiloxy) 2,3 -naphthalocyanine; silicon 6/5(tri-n- hexylsiloxy) naphthalocyanine; silicon naphthalocyanine; t-butylnaphthal
- Exemplary nile blue derivatives include benzo[a]phenothiazinium, 5-amino-9- diethylamino-; benzo[a]phenothiazinium, 5-amino-9-diethylamino-6-iodo-; benzo[a]phenothiazinium, 5-benzylamino-9-diethylamino-; benzo[a]phenoxazinium, 5- amino-6,8-dibromo-9-ethylamino-; benzo[a]phenoxazinium, 5-amino-6,8-diiodo-9- ethylamino-; benzo[a]phenoxazinium, 5-amino-6-bromo-9-diethylamino-; benzo[a]phenoxazinium, 5-amino-6-bromo-9-diethylamino-; benzo[a]phenoxazinium, 5-amino-9-diethylamino-(n
- Exemplary ⁇ SAIDs include benoxaprofen; ca ⁇ rofen; ca ⁇ rofen dechlorinated (2-(2-carbazolyl) propionic acid); ca ⁇ rofen (3-chlorocarbazole); chlorobenoxaprofen; 2,4-dichlorobenoxaprofen; cinoxacin; ciprofloxacin; decarboxy-ketoprofen; decarboxy-suprofen; decarboxy- benoxaprofen; decarboxy-tiaprofenic acid; enoxacin; fleroxacin; fleroxacin-N-oxide; flumequine; indoprofen; ketoprofen; lomelfloxacin; 2-methyl-4-oxo-2H-l,2- benzothiazine- 1,1 -dioxide; N-demethyl fleroxacin; nabumetone; nalidixic acid; nap
- Exemplary perylenequinones include hypericins such as hypericin; hypericin monobasic sodium salt; di-aluminum hypericin; di-copper hypericin; gadolinium hypericin; terbium hypericin, hypocrellins such as acetoxy hypocrellin A; acetoxy hypocrellin B; acetoxy wohypocrellin A; acetoxy /50-hypocrellin B; 3,10-6/5[2-(2- aminoethylamino)ethanol] hypocrellin B; 3,10-6/5[2-(2-aminoethoxy)ethanol] hypocrellin B; 3,10-t>/5[4-(2-aminoethyl)mo ⁇ holine] hypocrellin B; n-butylaminated hypocrellin B; 3,10-6/5(butylamine) hypocrellin B; 4,9- ⁇ /5(butylamine) hypocrellin B; carboxylic acid hypocrellin B; cystamine-hyp
- Exemplary pheophorbides include pheophorbide a; methyl 13'-deoxy-20-formyl- 7,8-v/c-dihydro-bacterio-/we5 ⁇ -pheophorbide a; methyl-2-(l -dodecyloxyethyl)-2-devinyl- pyropheophorbide a; methyl-2-(l-heptyl-oxyethyl)-2-devinyl-pyropheophorbide a; methyl-2-(l -hexyl-oxyethyl)-2-devinyl-pyropheophorbide a methyl-2-(l -methoxy- ethyl)-2-devinyl-pyropheophorbide a; methyl-2-(l-pentyl-oxyethyl)-2-devinyl- pyropheophorbide a; magnesium methyl bacteriopheophorbide
- Exemplary pheophytins include bacteriopheophytin a bacteriopheophytin b; bacteriopheophytin c; bacteriopheophytin d; 10-hydroxy pheophytin a; pheophytin; pheophytin a and protopheophytin.
- Exemplary photosensitizer dimers and conjugates include aluminum mono-(6- carboxy-pentyl-amino-sulfonyl)-trisulfophthalocyanine bovine serum albumin conjugate; dihematopo ⁇ hyrin ether (ester); dihematopo ⁇ hyrin ether; dihematopo ⁇ hyrin ether (ester)-chlorin; hematopo ⁇ hyrin-chlorin ester; hematopo ⁇ hyrin-low density lipoprotein conjugate; hematopo ⁇ hyrin-high density lipoprotein conjugate; po ⁇ hine-2,7,18- tripropanoic acid, 13,13'-(l,3-propanediyl)6/5[3,8,12,17-tetramethyl]-; po ⁇ hine-2,7,18- tripropanoic acid, 13,13'-(l,l l-undecanediyl)6/5[3,8,12
- Exemplary phthalocyanines include (diol) (t-butyl) 3 -phthalocyanine; (t-butyl) 4 - phthalocyanine; c/5-octabutoxy-dibenzo-dinaphtho-po ⁇ hyrazine; tran5-octabutoxy- dibenzo-dinaphtho-po ⁇ hyrazine; 2,3 ,9, 10, 16, 17,23 ,24-octakis2-ethoxyethoxy) phthalocyanine; 2,3,9,10,16,17,23,24-octakis(3,6-dioxaheptyloxy) phthalocyanine; octa- n-butoxy phthalocyanine; phthalocyanine; phthalocyanine sulfonate; phthalocyanine tetrasulphonate; phthalocyanine tetrasulfonate; t-butyl-phthalocyanine
- Exemplary po ⁇ hycenes include 2,3-(2 -carboxy-2 4 -methoxycarbonyl benzo)-7, 12,17-tris(2-methoxyethyl) po ⁇ hycene; 2-(2-hydroxyethyl)-7, 12, 17-tri(2- methoxyethyl) po ⁇ hycene; 2-(2-hydroxyethyl)-7,12,17-tri-n-propyl-po ⁇ hycene; 2-(2- methoxyethyl)-7, 12, 17-tri-n-propyl-po ⁇ hycene; 2,7, 12,17-tetrakis(2-methoxyethyl) po ⁇ hycene; 2,7,12,17-tetrakis(2-methoxyethyl)-9-hydroxy-po ⁇ hycene; 2,7,12,17- tetrakis(2-methoxyethyl)-9-hydroxy-po ⁇ hycene
- Exemplary po ⁇ hyrins include 5-azaprotopo ⁇ hyrin dimethylester; 6/5-po ⁇ hyrin; copropo ⁇ hyrin III; copropo ⁇ hyrin III tetramethylester; deuteropo ⁇ hyrin; deuteropo ⁇ hyrin IX dimethylester; diformyldeuteropo ⁇ hyrin IX dimethylester; dodecaphenylpo ⁇ hyrin; hematopo ⁇ hyrin; hematopo ⁇ hyrin (8 ⁇ M); hematopo ⁇ hyrin (400 ⁇ M); hematopo ⁇ hyrin (3 ⁇ M); hematopo ⁇ hyrin (18 ⁇ M); hematopo ⁇ hyrin (30 ⁇ M); hematopo ⁇ hyrin (67 ⁇ M); hematopo ⁇ hyrin (150 ⁇ M); hematopo ⁇ hyrin IX
- Exemplary psoralens include psoralen; 5-methoxypsoralen; 8-methoxypsoralen; 5,8-dimethoxypsoralen; 3-carbethoxypsoralen; 3-carbethoxy-pseudopsoralen; 8- hydroxypsoralen; pseudopsoralen; 4,5',8-trimethylpsoralen; allopsoralen; 3-aceto- allopsoralen; 4,7-dimethyl-allopsoralen; 4,7,4'-trimethyl-allopsoralen; 4,7,5'-trimethyl- allopsoralen; isopseudopsoralen; 3-acetoisopseudopsoralen; 4,5'-dimethyl- isopseudopsoralen; 5',7-dimethyl-isopseudopsoralen; pseudoisopsoralen; 3- acetopseudoisopsoralen; 3/4',5'-trimethyl-aza-psoralen; 4,4',8-trimethyl-5'
- Exemplary pu ⁇ urins include octaethylpu ⁇ urin; octaethylpu ⁇ urin zinc; oxidized octaethylpu ⁇ urin; reduced octaethylpu ⁇ urin; reduced octaethylpu ⁇ urin tin; pu ⁇ urin 18; pu ⁇ urin-18; pu ⁇ urin-18-methyl ester; pu ⁇ urin; tin ethyl etiopu ⁇ urin I; Zn(II) aetio- pu ⁇ urin ethyl ester; and zinc etiopu ⁇ urin.
- Exemplary quinones include l-amino-4,5-dimethoxy anthraquinone; 1,5-diamino- 4,8-dimethoxy anthraquinone; l,8-diamino-4,5-dimethoxy anthraquinone; 2,5-diamino- 1 ,8-dihydroxy anthraquinone; 2,7-diamino-l,8-dihydroxy anthraquinone; 4,5-diamino- 1,8-dihydroxy anthraquinone; mono-methylated 4,5- or 2,7-diamino- 1,8-dihydroxy anthraquinone; anthralin (keto form); anthralin; anthralin anion; 1,8-dihydroxy anthraquinone; 1,8-dihydroxy anthraquinone (Chrysazin); 1,2-dihydroxy anthraquinone; 1 ,2-dihydroxy an
- Exemplary retinoids include all-tran5 retinal; C ⁇ aldehyde; C 22 aldehyde; t l-cis retinal; 13-c/5 retinal; retinal; and retinal palmitate.
- Exemplary rhodamines include 4,5-dibromo-rhodamine methyl ester; 4,5- dibromo-rhodamine n-butyl ester; rhodamine 101 methyl ester; rhodamine 123; rhodamine 6G; rhodamine 6G hexyl ester; tetrabromo-rhodamine 123; and tetramethyl- rhodamine ethyl ester.
- Exemplary thiophenes include terthiophenes such as 2,2':5',2"-terthiophene; 2,2':5',2"-terthiophene-5-carboxamide; 2,2':5',2"-terthiophene-5-carboxylic acid;
- Exemplary verdins include copro (II) verdin trimethyl ester; deuteroverdin methyl ester; mesoverdin methyl ester; and zinc methyl pyroverdin.
- Exemplary vitamins include ergosterol (provitamin D2); hexamethyl-Co a Co 6- dicyano-7-de(carboxymethyl)-7,8-didehydro-cobyrinate (Pyrocobester); pyrocobester; and vitamin D3.
- Exemplary xanthene dyes include Eosin B (4',5'-dibromo,2',7'-dinitro- fluorescein, dianion); eosin Y; eosin Y (2',4',5',7'-tetrabromo-fluorescein, dianion); eosin (2',4',5',7'-tetrabromo-fluorescein, dianion); eosin (2',4',5',7'-tetrabromo-fluorescein, dianion) methyl ester; eosin (2',4',5',7'-tetrabromo-fluorescein, monoanion) p- isopropylbenzyl ester; eosin derivative (2',7'-dibromo-fluorescein, dianion); eosin derivative (4',5'-dibro
- any of the photoactive compounds described above can be used in the method of the invention; of course, mixtures of two or more photoactive compounds can also be used; however, the effectiveness of the treatment depends on the abso ⁇ tion of light by the photoactive compound so that if mixtures are used, components with similar abso ⁇ tion maxima are prefe ⁇ ed.
- the invention is practiced with light of a broader range of wavelengths or of discrete (or non-overlapping wavelengths), combinations of photoactive compounds with abso ⁇ tion spectra co ⁇ esponding to wavelengths within the broader range or within the wavelengths present may be used.
- the photoactive agent is formulated so as to provide an effective concentration to the target ocular tissue.
- the photoactive agent may be coupled to a specific binding ligand which may bind to a specific surface component of the target ocular tissue or, if desired, by formulation with a carrier that delivers higher concentrations to the target tissue.
- the formulation may be a liposomal formulation, an emulsion, or simply an aqueous solution. Buffers and other excipients may also be added. Gelling agents and other excipients may also be employed. The nature of the formulation will depend in part on the mode of administration and on the nature of the photoactive agent selected.
- any pharmaceutically acceptable excipient, or combination thereof, appropriate to the particular photoactive compound may be used.
- the photoactive compound may be administered as an aqueous composition, as a transmucosal or transdermal composition, or in an oral formulation.
- the formulation may also include liposomes.
- Liposomal compositions are particularly prefe ⁇ ed especially where the photoactive agent is a green po ⁇ hyrin.
- Liposomal formulations are believed to deliver the green po ⁇ hyrin selectively to the low-density lipoprotein component of plasma which, in turn acts as a carrier to deliver the active ingredient more effectively to the desired site.
- Increased numbers of LDL receptors have been shown to be associated with neovascularization, and by increasing the partitioning of the green po ⁇ hyrin into the lipoprotein phase of the blood, it appears to be delivered more efficiently to neovasculature.
- the method of the invention is particularly effective where the loss of visual acuity in the patient is associated with unwanted neovasculature.
- Green po ⁇ hyrins, and in particular BPD-MA strongly interact with such hpoproteins.
- LDL itself can be used as a carrier, but LDL is considerably more expensive and less practical than a liposomal formulation.
- LDL, or preferably liposomes are thus preferred carriers for the green po ⁇ hyrins since green po ⁇ hyrins strongly interact with Hpoproteins and are easily packaged in liposomes.
- Compositions of green po ⁇ hyrins involving lipocomplexes, including liposomes are described in U.S. Patent 5,214,036 and in U.S. Patent 6074666, the disclosures of both of these being inco ⁇ orated herein by reference.
- Liposomal BPD-MA for intravenous administration can also be obtained from QLT Inc., Vancouver, British Columbia.
- the photoactive compound can be administered in any of a wide variety of ways, for example, orally, parenterally, or rectally, or the compound may be placed directly in the eye.
- Parenteral administration such as intravenous, intramuscular, or subcutaneous, is prefe ⁇ ed.
- Intravenous injection or infusion are especially prefe ⁇ ed.
- Localized administration including topical administration, may also be used.
- the dose of photoactive compound can vary widely depending on the mode of administration; the formulation in which it is carried, such as in the form of liposomes; or whether it is coupled to a target-specific ligand, such as an antibody or an immunologically active fragment.
- a target-specific ligand such as an antibody or an immunologically active fragment.
- the PS concentration in the formulation to be administered will depend on the nature of the tissue to be treated, the manner in which the formulation is administered, and the nature of the PS. Typical concentrations, however, are in the range of about 1 ng/ml to about 10 ⁇ g/ml, preferably about 2 ng/ml to about 1 ⁇ g/ml, and typically in the range of about 10 ng/ml to about 100 ng/ml. However, these values are merely suggestions and may not apply to all PSs.
- a typical dosage is of the range of 0.1-50 mg/M 2 (of body surface area) preferably from about 1-10 mg/M 2 and even more preferably about 2-8mg/M 2 , and most preferably about 6 mg/ M 2 .
- verteporfin is the photoactive agent, it is preferably used at about 6 mg/ M 2 .
- these values are merely suggestions and may not apply to all photosensitizers. 6 mg/m 2 is approximately 0.15 mg/kg.
- Systemic administration can also be stated in terms of amount of PS to body weight of the subject being treated. Dosages for this invention stated in such terms are less than about 10 ⁇ g/kg to 100 mg/kg body weight, preferably less than about 10 mg/kg, more preferably about 0.15 mg/kg in humans.
- the PS is infused into a subject over a short period, such as, but not limited to, about 5 to about 120 minutes, about 10 to about 90 minutes, about 20 to about 60 minutes, or about 30 to 45 minutes. Particularly prefe ⁇ ed is an infusion over 10 minutes.
- the various parameters used for effective, selective photodynamic therapy in the invention are inte ⁇ elated. Therefore, the dose should also be adjusted with respect to other parameters, for example, fluence, i ⁇ adiance, duration of the light used in photodynamic therapy, and time interval between administration of the dose and the therapeutic irradiation. All of these parameters should be adjusted to produce significant enhancement of visual acuity without significant damage to the eye tissue.
- the fluence required to close choroidal neovascular tissue tends to increase.
- the target ocular tissue is i ⁇ adiated at the wavelength absorbed by the agent selected.
- the spectra for the photoactive compounds described above, as well as wavelengths required for PS activation are known in the art. I ⁇ adiation of the admimstered PS is preferably at the wavelength(s) absorbed by the compound selected.
- the desired wavelength range is generally between about 550 and 695 nm. A wavelength in this range is especially prefe ⁇ ed for enhanced penetration into bodily tissues.
- Prefe ⁇ ed wavelengths for the practice of the invention are at about 685-695 nm, particularly at about 686, about 687, about 688, about 689, about 690, about 691, and about 692 nm.
- Photoactive compound photosensitizer or PS
- I ⁇ adiation of the administered photosensitizer is preferably at the wavelength absorbed by the photosensitizer selected.
- the photoactive compound in its excited state is thought to interact with other compounds to form reactive intermediates, such as singlet oxygen, which can cause disruption of cellular structures.
- Possible cellular targets include the cell membrane, mitochondria, lysosomal membranes, and the nucleus.
- Evidence from tumor and neovascular models indicates that occlusion of the vasculature is a major mechanism of photodynamic therapy, which occurs by damage to endothelial cells, with subsequent platelet adhesion, degranulation, and thrombus formation.
- the fluence during the i ⁇ adiating treatment can vary widely, depending on type of tissue, depth of target tissue, and the amount of overlying fluid or blood, but preferably varies from about 20-200 Joules/cm 2 .
- the i ⁇ adiation levels will be in the range generally employed for PDT treatment of CNV as known in the art. Typical levels for the practice of the invention are in the range of about 12.5, 25, 50, 75, and 100 J/cm 2 .
- the radiation can be supplied by any convenient source using a wavelength absorbed by the photosensitizer used. Examples of sources for use in the present methods include, but are not limited to, any assembly capable of producing visible light.
- the total PDT dose depends on the balance of at least the concentration of PS employed, light intensity (fluence rate), and time of i ⁇ adiation which determines total energy.
- concentration of PS employed concentration of PS employed
- fluence rate light intensity (fluence rate)
- time of i ⁇ adiation time of i ⁇ adiation which determines total energy.
- the i ⁇ adiance typically varies from about 150-900 mW/cm 2 , with the range between about 150-600 mW/cm 2 being preferred. However, the use of higher i ⁇ adiances may be selected as effective and having the advantage of shortening treatment times.
- irradiances in the range of 300-600 mW/cm 2 are prefe ⁇ ed.
- Prefe ⁇ ed rates for use with green po ⁇ hyrins or BPDs in general are from about 200 to
- electromagnetic radiation unless other wise indicated, is meant generally to refer to the visible light range of the electromagnetic spectrum, generally including wavelengths between 400nm and 700nm.
- visible light and “visible light radiation” and variations thereof are meant to be encompassed within the scope of the term “electromagnetic radiation.”
- this term may also be used herein to refer to electromagnetic radiation within the ultraviolet (including wavelengths below 400nm) and infrared spectra (including wavelengths above 700nm).
- the optimum time following photoactive agent administration until light treatment can also vary widely depending on the mode of administration and the form of administration and the specific ocular tissue or condition being targeted.
- Typical times after administration of the photoactive agent range from about 1 minute to about 3 hours after the start of the infusion of the photoactive compound, preferably about 10-45 minutes, and more preferably 15-30 minutes. Fifteen minutes after the start of a 10 minute infusion has been shown to be effective in the use of verteporfin PDT to treat predominantly classic CNV. With occult CNV, delayed light treatment, which is longer than 15 minutes, but less than about 45 minutes may be prefe ⁇ ed. Preferably, i ⁇ adiation is provided between about 15 and about 30 minutes after the start of a 10 minute infusion of verteporfin when treating occult lesions. In a particularly prefe ⁇ ed embodiment, light is administered 30 minutes after the start of a 10 minute infusion of verteporfin. The incubation before i ⁇ adiation may occur in the dark or low-level light may be supplied during PS administration.
- the duration of light i ⁇ adiation depends on the fluence desired; for an i ⁇ adiance of 600 mW/cm 2 a fluence of 50 J/cm 2 requires 83 seconds of i ⁇ adiation; 150 J/cm 2 requires 249 seconds of irradiation. With verteporfin PDT, a fluence of between 30 and 50 J/ cm 2 is prefe ⁇ ed.
- Parameters that are monitored in AMD patients or subjects include the progression from baseline of classic CNV in the lesion, progression from baseline of occult CNV in the lesion, change from baseline in greatest linear dimension of the entire CNV lesion, change from baseline in area of the entire lesion including CNV, natural scar and obscuring features (measured in Macular Photocoagulation Study Disc Area, MPS DA), and change from baseline in area of the entire lesion plus su ⁇ ounding atrophy (measured in MPS DA).
- Efficacy of PDT treatment is measured primarily by evaluation of visual acuity following treatment. This is done using means similar to that described above. Parameters that are typically monitored in evaluation of a treatment protocol are gain or loss of letters from baseline (e.g. percent of subjects gaining/losing 15 letters or more, percent of subjects losing 30 letters or more, best-co ⁇ ected visual acuity decreasing less than 34 letters, etc.), the time it takes to lose letters (e.g. time to lose 15 or more letters, time to lose 30 or more letters) and absolute changes from baseline visual acuity scores.
- neovascular leakage After the initial PDT treatment, an angiographic examination is carried out to determine if neovascular leakage has recu ⁇ ed. If upon angiographic evaluation, it is apparent that neovascular leakage is recurring, the subject can be retreated.
- the visual acuity of subjects are measured based on the procedure developed for the Early Treatment Diabetic Retinopathy Study (ETDRS). The following equipment is used:
- Retroilluminated Chart R from the ETDRS (modified Bailey-Lovie chart) visual acuity chart set; trial lens frames; wire- rimmed lens set, with positive or negative cylinder lenses; +0.37 and -0.37 spherical lenses; Jackson cross-cylinders of 0.25, 0.5, and 1.00 diopters; pinhole occluder and tissues.
- ETDRS modified Bailey-Lovie chart
- the subject's present glasses (spectacles) for distance viewing may be measured with a lensometer, and these measurements used as the beginning approximate refraction.
- Refractions may be performed with positive or negative cylinder power. Each center must designate positive or negative cylinder and must use the same designation throughout the study. If the subject does not wear glasses for distance vision, retinoscopy or autorefraction may be performed.
- the beginning approximate refraction should be no lens co ⁇ ection or piano.
- the best co ⁇ ection determined from subjective refraction at each visit should be recorded on the Record of Subjective Refraction maintained for each subject.
- the refraction recorded at the previous visit should be used as the beginning approximate refraction for each eye. Only at the baseline examination should the distance prescription worn in glasses be used.
- each eye should be refracted at 2 meters unless the visual acuity measured at this distance on the chart used for refraction (Chart R) is worse than 20/320.
- the eye is refracted at 1 meter with a + 2.00 and - 2.00 sphere only.
- the vision should be checked with a pinhole to see whether reduced vision is due, at least in part, to larger refractive error. If there is no improvement with pinhole, the non-study eye is exempt from refraction.
- the visual acuity of the non-study eye may be measured and recorded in the usual way, beginning at 2 meters first, with the beginning approximate refractive co ⁇ ection.
- Subjects who arrive for examination wearing contact lenses may be refracted over their lenses starting with piano.
- the lens co ⁇ ection recorded may be the final co ⁇ ection in the trial frame at the end of refraction and spherical refinement in the visual acuity lane.
- Co ⁇ ected aphakic subjects including those with intraocular lenses, may undergo subjective refraction as specified below.
- a +10.00 diopter sphere may be added to the trial frame as the beginning approximate refraction.
- Scoring Best-Co ⁇ ected Visual Acuity may be conducted as follows: the examiner records each letter identified co ⁇ ectly by circling the co ⁇ esponding letter on the Visual Acuity Worksheet. Letters read inco ⁇ ectly are marked with an "X" and letters for which no guesses are made are not marked on the form. Each letter read co ⁇ ectly is scored as one point. The score for each line (which is zero if no letters are read correctly)
- Fundus photographs and fluorescein angiograms are obtained at a screening visit, within 7 days prior to randomization. Fundus photographs and fluorescein angiograms are obtained at follow-up visits every three months thereafter for a period of up to two years.
- 2.6X are recommended for the study.
- the Zeiss 30° camera is most prefe ⁇ ed camera because of the superior quality of the image when compared to the other available cameras.
- a 45° camera is acceptable according to the protocol, as long as the magnification is still within the acceptable range of 2.4X to 2.6X. Cameras with fields of 25° or 60° are not acceptable.
- the WILMER READING CENTER template of MPS Disc Area Circles labeled for the Zeiss 30° camera dated 10/96 were used to determine the area of on fluorescein angiograms from any of the cameras identified above. It also is used to determine the size category for the greatest linear dimension of the lesion to be treated.
- a millimeter scale which is used by the treating ophthalmologist directly on the angiogram to measure the greatest linear dimension of the lesion to be treated.
- This reticle has been used to measure the greatest linear dimension of the MPS Disc Area Template circles and create a conversion table found in Table 1.
- CNV choroidal neovascular
- the entire fluorescein angiographic sequence is reviewed to determine if there is hyperfluorescent leakage consistent with the presence of CNV.
- the presence of other lesion components known as features that obscure the delineation of CNN are also noted, such as contiguous areas of blood, blocked fluorescence, or serous PED.
- the reader determines if C ⁇ V is indeed present and is the predominant lesion component (> 50% of the lesion) or whether the area involved by the sum of all obscuring components predominates (CNV ⁇ 50% of lesion). If no leakage from CNV is present, a "no" grade is indicated. Areas of staining fibrous tissue are considered as non-CNV components and are included in determining the percent of the lesion that is CNN.
- Choroidal neovascular tissue can occur anywhere within the fundus.
- Field 2 is used to determine if the choroidal neovascular leakage underlies the geometric center of the foveal avascular zone (subfoveal) or whether it clearly spares the foveal center (not subfoveal).
- the reader can say with relative certainty that the C ⁇ N is very likely to be under the foveal center (probably subfoveal).
- the entire neovascular lesion is studied throughout the fluorescein angiogram to determine the lesion components which are present.
- Each lesion component that may comprise a neovascular lesion is listed here, and the reader must identify whether each component is definitely present (yes), questionably present (questionable), or definitely absent (no).
- the reader prepares a tracing of landmark vessels and lesion components using the dokumator and the available photographs.
- Areas of classic C ⁇ V are identified if the angiogram shows an area of bright, well-demarcated hyperfluorescence in the early phase of the angiogram, with progressive dye leakage into the overlying subsensory retinal space in the late phase of the angiogram.
- a vascular or tubular matrix is variably present.
- classic C ⁇ V the readers determine the relative area involved with this component and compare that area to the sum of the area involved with all other lesion components, if present. The reader determines if classic C ⁇ V is the predominant lesion component (> 50%) or if the total of other components predominate (classic C ⁇ V ⁇ 50%).
- Occult C ⁇ V is identified when there is staining or leakage from a fibrovascular pigment epithelial detachment (PED) or when there is hyperfluorescent leakage at the level of the RPE that represents late leakage ofan undetermined source.
- Fibrovascular PED represents areas of i ⁇ egular elevation of the pigment epithelium consisting of speckled or granular hyperfluorescence that is not as bright as classic C ⁇ V, frequently appearing within one to two minutes after fluorescein injection (later than classic C ⁇ V), with persistence of staining or leakage of dye in the late frames.
- Late leakage of an undetermined source is areas of leakage at the level of the retinal pigment epithelium in the late phase of the angiogram without classic CNV or fibrovascular PED discernible in the early or middle phase of the angiogram to account for the leakage.
- Blocked fluorescence that is contiguous to other lesion components, visualized at any time during the transit, is considered a lesion component itself. This may co ⁇ espond to pigment hype ⁇ lasia on color fundus photographs or possibly fibrous tissue, but will not co ⁇ espond to visible blood. This is variably elevated but may be perceived as flat at the level of the RPE.
- a serous pigment epithelial detachment that is contiguous to other lesion components is also considered a lesion component itself.
- Serous PED is identified when there is a regular degree of elevation to the pigment epithelium, often dome shaped in its contour, with sha ⁇ ly demarcated borders. These regions hyperfluoresce early, generally of a uniform nature, and have persistent hyperfluorescence and constant borders in the late phases of the angiogram. They lack a granular appearance and the perimeter of the configuration is often regularly shaped and round.
- the lesion to be measured is comprised of CNV (classic plus occult CNV, if present), contiguous natural scarring associated with the CNV (such as non-geographic atrophy or fibrosis which may stain rather than leak during angiography), and features that obscure the boundaries of CNV such as contiguous blood, blocked fluorescence (either due to fibrosis or pigmentation) and/or serous PEDs.
- Previous laser treatment if present is considered in addressing question 9, but it is not a lesion component to be used in size calculations. Contiguous zones of geographic atrophy are not included in the area.
- the Zeiss 30° MPS disc area template is used for all photographs taken on cameras with magnifications ranging from 2.4x to 2.6x.
- This template is placed directly over a representative frame of the fluorescein angiogram that includes all lesion components, prior to significant leakage.
- the template is centered with reference to the center of the lesion and the circle is selected that best inco ⁇ orates all aspects of the lesion. If the lesion is i ⁇ egularly shaped such that a portion or portions goes beyond the perimeter of the circle, then the reader excises this portion of the lesion from the exterior of the circle and inco ⁇ orates it into available portions of the circle.
- Subjects having, suspected of having, or otherwise afflicted with occult neovascular lesions were evaluated for best co ⁇ ected visual acuity as outlined in
- Example 1 and their lesion size determined angiographically as outlined in Example 2. Subjects were included if they had a best co ⁇ ected vision of at least 50 letters, co ⁇ esponding to approximately 20/100, and had a CNV lesion that is occult, with no evidence of classic CNV. The greatest linear dimension of the entire CNV lesion was 5.4 square millimeters, co ⁇ esponding to 9 Disc Areas. Subjects were evaluated for visual acuity and lesion size about 1 week prior to treatment. Subjects were randomly assigned to a treatment group and a placebo group.
- a 15mg-vial of liposomally-formulated verteporfin (Verteporfin for Injection (VisudyneTM) was reconstituted with 7 mL of sterile water for injection to provide 7.5 mL containing a final concentration of 2 mg/mL.
- the volume of reconstituted drug required to achieve a dose of 6 mg/M 2 (based upon the height and weight of the subject, calculated from a nomogram) was withdrawn from the vial and diluted with 5% dextrose for injection to make a total infusion volume of 30 mL.
- the full infusion volume was administered intravenously over 10 minutes using an appropriate syringe pump and in-line filter.
- Subjects were evaluated by fluorescein angiography approximately every three months, and their best co ⁇ ected visual acuity was assessed. Subjects were retreated if evidence of CNV leakage was detected by fluorescein angiography.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02703362A EP1357912B9 (en) | 2001-02-06 | 2002-02-06 | Photodynamic therapy of occult choroidal neovascularization linked to age-related macular degeneration |
AU2002236988A AU2002236988A1 (en) | 2001-02-06 | 2002-02-06 | Photodynamic therapy of occult choroidal neovascularization linked to age-related macular degeneration |
CA2437563A CA2437563C (en) | 2001-02-06 | 2002-02-06 | Photodynamic therapy of occult age-related macular degeneration |
ES02703362T ES2386718T3 (en) | 2001-02-06 | 2002-02-06 | Photodynamic therapy for macular degeneration associated with hidden age |
AT02703362T ATE554763T1 (en) | 2001-02-06 | 2002-02-06 | PHOTODYNAMIC THERAPY OF OCCULT CHORIOIDAL NEOVASCULARIZATION ASSOCIATED WITH AGE-RELATED MACULAR DEGENERATION |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26694001P | 2001-02-06 | 2001-02-06 | |
US60/266,940 | 2001-02-06 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002062386A2 true WO2002062386A2 (en) | 2002-08-15 |
WO2002062386A3 WO2002062386A3 (en) | 2002-10-24 |
Family
ID=23016614
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/003758 WO2002062386A2 (en) | 2001-02-06 | 2002-02-06 | Photodynamic therapy of occult choroidal neovascularization linked to age-related macular degeneration |
Country Status (7)
Country | Link |
---|---|
US (1) | US8034803B2 (en) |
EP (1) | EP1357912B9 (en) |
AT (1) | ATE554763T1 (en) |
AU (1) | AU2002236988A1 (en) |
CA (1) | CA2437563C (en) |
ES (1) | ES2386718T3 (en) |
WO (1) | WO2002062386A2 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002060482A2 (en) * | 2001-01-30 | 2002-08-08 | Altachem Pharma, Ltd. | Perylenequinones for use with immunotherapy agents |
WO2002062385A2 (en) * | 2001-02-06 | 2002-08-15 | Qlt, Inc. | Method to prevent vision loss |
WO2002062384A2 (en) * | 2001-02-06 | 2002-08-15 | Qlt Inc. | Reduced fluence rate pdt |
US7753943B2 (en) | 2001-02-06 | 2010-07-13 | Qlt Inc. | Reduced fluence rate PDT |
US8454991B2 (en) | 2006-07-24 | 2013-06-04 | Quest Pharmatech Inc. | Method and device for photodynamic therapy |
US8506931B2 (en) | 2005-08-10 | 2013-08-13 | Quest Pharmatech Inc. | Perylenequinone derivatives and uses thereof |
WO2016094673A1 (en) * | 2014-12-11 | 2016-06-16 | Bayer Healthcare Llc | Treatment of age related macular degeneration with a small active choroidal neovascularization lesion |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7303578B2 (en) * | 2001-11-01 | 2007-12-04 | Photothera, Inc. | Device and method for providing phototherapy to the brain |
US20050159793A1 (en) * | 2002-07-02 | 2005-07-21 | Jackson Streeter | Methods for treating macular degeneration |
WO2004034889A2 (en) * | 2002-10-18 | 2004-04-29 | The Regents Of The University Of California | Photodynamic therapy for ocular neovascularization |
US7521481B2 (en) | 2003-02-27 | 2009-04-21 | Mclaurin Joanne | Methods of preventing, treating and diagnosing disorders of protein aggregation |
CA2530166A1 (en) * | 2003-03-07 | 2004-09-23 | Randolph D. Glickman | Antibody-targeted photodynamic therapy |
US20060094753A1 (en) * | 2004-10-29 | 2006-05-04 | Alcon, Inc. | Use of inhibitors of Jun N-terminal kinases for the treatment of glaucomatous retinopathy and ocular diseases |
US20060189582A1 (en) * | 2004-11-17 | 2006-08-24 | Mclaurin Joanne | Compositions and methods for treatment of disorders of protein aggregation |
CA2626005A1 (en) * | 2005-10-13 | 2007-10-25 | Waratah Pharmaceuticals Inc. | Inositol derivatives and their uses in the treatment of diseases characterized by abnormal protein folding or aggregation or amyloid formation, deposition, accumulation or persistence |
WO2007129221A2 (en) * | 2006-02-17 | 2007-11-15 | Waratah Parmaceuticals Inc | Compositions comprising an epi-inositol compounds and methods for treatment of disorders of protein aggregation |
US20070197452A1 (en) * | 2006-02-17 | 2007-08-23 | Mclaurin Joanne | Treatment of amyloid-related diseases |
MX2008011553A (en) * | 2006-03-09 | 2008-12-09 | Waratah Pharmaceuticals Inc | A cyclohexane polyalcohol formulation for treatment of disorders of protein aggregation. |
CA2652449A1 (en) * | 2006-05-19 | 2007-11-29 | Waratah Pharmaceuticals Inc. | Screening methods for amyloid beta modulators |
US20100173960A1 (en) * | 2006-09-21 | 2010-07-08 | Antonio Cruz | The Combination of a Cyclohexanehexol and a NSAID for the Treatment of Neurodegenerative Diseases |
CA2670405A1 (en) * | 2006-11-24 | 2008-05-29 | Waratah Pharmaceuticals Inc. | Combination treatments for alzheimer's disease and related neurodegenerative diseases |
CA2683546A1 (en) * | 2007-04-12 | 2008-10-23 | Joanne Mclaurin | Use of cyclohexanehexol derivatives in the treatment of .alpha.-synucleinopathies |
PL2148667T3 (en) * | 2007-04-12 | 2013-11-29 | Waratah Pharmaceuticals Inc | Use of cyclohexanehexol derivatives in the treatment of ocular diseases |
CA2683548A1 (en) * | 2007-04-12 | 2008-10-23 | Joanne Mclaurin | Use of cyclohexanehexol derivatives for the treatment of polyglutamine diseases |
WO2008124931A1 (en) * | 2007-04-12 | 2008-10-23 | Joanne Mclaurin | Use of cyclohexanehexol derivatives in the treatment of amyotrophic lateral sclerosis |
WO2010040232A1 (en) * | 2008-10-09 | 2010-04-15 | Waratah Pharmaceuticals Inc. | Use of scyllo-inositols for the treatment of macular degeneration-related disorders |
US8829020B2 (en) | 2009-07-16 | 2014-09-09 | Mallinckrodt Llc | Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers |
TWI702955B (en) | 2012-05-15 | 2020-09-01 | 澳大利亞商艾佛蘭屈澳洲私營有限公司 | Treatment of amd using aav sflt-1 |
US10000741B2 (en) | 2014-03-17 | 2018-06-19 | Adverum Biotechnologies, Inc. | Compositions and methods for enhanced gene expression in cone cells |
CN107405507B (en) | 2015-03-02 | 2022-05-03 | 阿德夫拉姆生物技术股份有限公司 | Compositions and methods for intravitreal delivery of polynucleotides to retinal cones |
GB2545763A (en) | 2015-12-23 | 2017-06-28 | Adverum Biotechnologies Inc | Mutant viral capsid libraries and related systems and methods |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5798349A (en) * | 1994-03-14 | 1998-08-25 | The General Hospital Corporation | Use of green porphyrins to treat neovasculature in the eye |
US5935942A (en) * | 1994-12-14 | 1999-08-10 | Zeimer; Ran | Selective and non-invasive visualization or treatment of vasculature |
-
2002
- 2002-02-06 AT AT02703362T patent/ATE554763T1/en active
- 2002-02-06 AU AU2002236988A patent/AU2002236988A1/en not_active Abandoned
- 2002-02-06 CA CA2437563A patent/CA2437563C/en not_active Expired - Lifetime
- 2002-02-06 EP EP02703362A patent/EP1357912B9/en not_active Expired - Lifetime
- 2002-02-06 US US10/072,272 patent/US8034803B2/en not_active Expired - Lifetime
- 2002-02-06 WO PCT/US2002/003758 patent/WO2002062386A2/en not_active Application Discontinuation
- 2002-02-06 ES ES02703362T patent/ES2386718T3/en not_active Expired - Lifetime
Non-Patent Citations (1)
Title |
---|
None |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002060482A3 (en) * | 2001-01-30 | 2003-02-13 | Altachem Pharma Ltd | Perylenequinones for use with immunotherapy agents |
WO2002060482A2 (en) * | 2001-01-30 | 2002-08-08 | Altachem Pharma, Ltd. | Perylenequinones for use with immunotherapy agents |
US6800086B2 (en) | 2001-02-06 | 2004-10-05 | Qlt Inc. | Reduced fluence rate PDT |
WO2002062385A3 (en) * | 2001-02-06 | 2003-02-06 | Quadra Logic Tech Inc | Method to prevent vision loss |
WO2002062384A2 (en) * | 2001-02-06 | 2002-08-15 | Qlt Inc. | Reduced fluence rate pdt |
WO2002062384A3 (en) * | 2001-02-06 | 2003-05-15 | Quadra Logic Tech Inc | Reduced fluence rate pdt |
WO2002062385A2 (en) * | 2001-02-06 | 2002-08-15 | Qlt, Inc. | Method to prevent vision loss |
US7060695B2 (en) | 2001-02-06 | 2006-06-13 | Qlt, Inc. | Method to prevent vision loss |
US7753943B2 (en) | 2001-02-06 | 2010-07-13 | Qlt Inc. | Reduced fluence rate PDT |
US8506931B2 (en) | 2005-08-10 | 2013-08-13 | Quest Pharmatech Inc. | Perylenequinone derivatives and uses thereof |
US8758725B2 (en) | 2005-08-10 | 2014-06-24 | Quest Pharmatech Inc. | Perylenequinone derivatives and uses thereof |
US8454991B2 (en) | 2006-07-24 | 2013-06-04 | Quest Pharmatech Inc. | Method and device for photodynamic therapy |
WO2016094673A1 (en) * | 2014-12-11 | 2016-06-16 | Bayer Healthcare Llc | Treatment of age related macular degeneration with a small active choroidal neovascularization lesion |
JP2017537117A (en) * | 2014-12-11 | 2017-12-14 | バイエル・ヘルスケア・エルエルシーBayer HealthCare LLC | Treatment of age-related macular degeneration with small active choroidal neovascular lesions |
Also Published As
Publication number | Publication date |
---|---|
CA2437563A1 (en) | 2002-08-15 |
ATE554763T1 (en) | 2012-05-15 |
CA2437563C (en) | 2010-03-23 |
US20030087889A1 (en) | 2003-05-08 |
US8034803B2 (en) | 2011-10-11 |
WO2002062386A3 (en) | 2002-10-24 |
AU2002236988A1 (en) | 2002-08-19 |
EP1357912A2 (en) | 2003-11-05 |
ES2386718T3 (en) | 2012-08-28 |
EP1357912B9 (en) | 2012-06-13 |
EP1357912B1 (en) | 2012-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2437563C (en) | Photodynamic therapy of occult age-related macular degeneration | |
US7015240B2 (en) | Treatment of macular edema | |
US8106038B2 (en) | Method for reducing or preventing PDT related inflammation | |
CA2437557C (en) | Reduced total fluence photodynamic therapy of choroidal neovasculature in amd | |
US7060695B2 (en) | Method to prevent vision loss | |
US7753943B2 (en) | Reduced fluence rate PDT | |
AU2009327266B2 (en) | Combination of photodynamic therapy and anti-VEGF agents in the treatment of unwanted choroidal neovasculature | |
US6609014B1 (en) | Use of PDT to inhibit intimal hyperplasia | |
US20090192209A1 (en) | Extended treatment of tumors through vessel occlusion with light activated drugs | |
CA2391389A1 (en) | Use of pdt to inhibit intimal hyperplasia | |
US20040208855A1 (en) | Use of PDT to inhibit intimal hyperplasia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2437563 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002703362 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002703362 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |